

# Psoriasis




## What is Psoriasis?

Plaque psoriasis, otherwise known as psoriasis vulgaris, is a common, chronic, inflammatory disease characterized by a rapid, unpredictable production of skin cells, which leads to the formation of painful scaling and plaques.<sup>1</sup>

Plaque psoriasis substantially impairs patients' physical health, quality of life and work productivity.

## Common Locations of Psoriasis




## Symptoms

Psoriasis can include a number of different symptoms including:<sup>2</sup>

- Itching, pain, stinging, burning, or skin tightness
- Skin dryness, cracking, scaling, shedding or flaking, redness or bleeding

Psoriasis is associated with multiple comorbidities that are known to reduce life expectancy, including cardiovascular disease, metabolic syndrome, obesity, diabetes, inflammatory bowel disease and others.



Psoriasis has been reported to impact emotional well-being in almost 90% of patients, straining both personal and professional relationships and creating a socioeconomic burden related to lost opportunities and treatment expenses.<sup>1</sup>



## Prevalence

Psoriasis is a serious and growing global problem, impacting at least **100 MILLION** people worldwide.

Psoriasis affects **both sexes equally** and can initially be present at **any age**.<sup>1,3,4</sup>



## Treatment

Psoriasis treatments can reduce signs and symptoms of the disease, but cannot eradicate the disease altogether.

Current available treatments for moderate to severe psoriasis include:<sup>1</sup>

- Topical Therapy
- Phototherapy
- Systematic Therapy
- Biologics



Despite the availability of effective treatments for moderate to severe psoriasis, psoriasis remains significantly undertreated, with as many as 50 percent of patients struggling with insufficient disease control.<sup>1</sup>

There is a significant need for new or novel transformational oral therapies with an acceptable safety profile, that deliver significant skin clearance and provide a meaningful, positive impact on patients' lives.<sup>1</sup>

Bristol-Myers Squibb is committed to identifying and pursuing new treatment options and innovative development approaches to help deliver transformational medicines for patients with psoriasis and other autoimmune diseases.



1. Michalek, I. M., Loring, B., & John, S. M. (2016). Global report on psoriasis. Geneva, Switzerland: World Health Organization.  
2. Feldman, S. R., Mathias, S. D., Schenkel, B., Colwell, H. H., McQuarrie, K., Randazzo, B., & Han, C. (2016). Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary. *Journal of Dermatology & Dermatologic Surgery*, 20(1), 19-26. doi:10.1016/j.jdds.2015.07.004.  
3. Langley RGB et al. *Ann Rheum Dis*. 2005;64(Suppl II):ii18-ii23. doi: 10.1136/ard.2004.033217.  
4. Queiro R et al. *Rheumatology*. 2014;53:1178-1185. 5. Helmick CG et al. *Am J Prev Med*. 2014;47:37-45.